img

Global Neuroprotective Agents Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Neuroprotective Agents Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Neuroprotective agents are medications that can alter the course of metabolic events after the onset of ischemia and therefore have the potential to reduce stroke damage.
The global Neuroprotective Agents market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Neuroprotective Agents is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Neuroprotective Agents is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Neuroprotective Agents is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Neuroprotective Agents include Genervon Biopharmaceuticals, NeuroVive Pharmaceutical, Ceregene, Neuren Pharmaceuticals and Allon Therapeutics, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Neuroprotective Agents, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Neuroprotective Agents by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Neuroprotective Agents market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Neuroprotective Agents market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Genervon Biopharmaceuticals
NeuroVive Pharmaceutical
Ceregene
Neuren Pharmaceuticals
Allon Therapeutics
By Type
Cerebrovascular Diseases
Neurodegenerative Disorders
Ophthalmic Diseases
Traumatic CNS Injuries
By Application
Hospitals
Clinics
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Neuroprotective Agents in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Neuroprotective Agents manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuroprotective Agents sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Neuroprotective Agents Definition
1.2 Market by Type
1.2.1 Global Neuroprotective Agents Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Cerebrovascular Diseases
1.2.3 Neurodegenerative Disorders
1.2.4 Ophthalmic Diseases
1.2.5 Traumatic CNS Injuries
1.3 Market Segment by Application
1.3.1 Global Neuroprotective Agents Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Neuroprotective Agents Sales
2.1 Global Neuroprotective Agents Revenue Estimates and Forecasts 2018-2034
2.2 Global Neuroprotective Agents Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Neuroprotective Agents Revenue by Region
2.3.1 Global Neuroprotective Agents Revenue by Region (2018-2024)
2.3.2 Global Neuroprotective Agents Revenue by Region (2024-2034)
2.4 Global Neuroprotective Agents Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Neuroprotective Agents Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Neuroprotective Agents Sales Quantity by Region
2.6.1 Global Neuroprotective Agents Sales Quantity by Region (2018-2024)
2.6.2 Global Neuroprotective Agents Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Neuroprotective Agents Sales Quantity by Manufacturers
3.1.1 Global Neuroprotective Agents Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Neuroprotective Agents Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Neuroprotective Agents Sales in 2022
3.2 Global Neuroprotective Agents Revenue by Manufacturers
3.2.1 Global Neuroprotective Agents Revenue by Manufacturers (2018-2024)
3.2.2 Global Neuroprotective Agents Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Neuroprotective Agents Revenue in 2022
3.3 Global Neuroprotective Agents Sales Price by Manufacturers
3.4 Global Key Players of Neuroprotective Agents, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Neuroprotective Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Neuroprotective Agents, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Neuroprotective Agents, Product Offered and Application
3.8 Global Key Manufacturers of Neuroprotective Agents, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Neuroprotective Agents Sales Quantity by Type
4.1.1 Global Neuroprotective Agents Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Neuroprotective Agents Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Neuroprotective Agents Sales Quantity Market Share by Type (2018-2034)
4.2 Global Neuroprotective Agents Revenue by Type
4.2.1 Global Neuroprotective Agents Historical Revenue by Type (2018-2024)
4.2.2 Global Neuroprotective Agents Forecasted Revenue by Type (2024-2034)
4.2.3 Global Neuroprotective Agents Revenue Market Share by Type (2018-2034)
4.3 Global Neuroprotective Agents Price by Type
4.3.1 Global Neuroprotective Agents Price by Type (2018-2024)
4.3.2 Global Neuroprotective Agents Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Neuroprotective Agents Sales Quantity by Application
5.1.1 Global Neuroprotective Agents Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Neuroprotective Agents Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Neuroprotective Agents Sales Quantity Market Share by Application (2018-2034)
5.2 Global Neuroprotective Agents Revenue by Application
5.2.1 Global Neuroprotective Agents Historical Revenue by Application (2018-2024)
5.2.2 Global Neuroprotective Agents Forecasted Revenue by Application (2024-2034)
5.2.3 Global Neuroprotective Agents Revenue Market Share by Application (2018-2034)
5.3 Global Neuroprotective Agents Price by Application
5.3.1 Global Neuroprotective Agents Price by Application (2018-2024)
5.3.2 Global Neuroprotective Agents Price Forecast by Application (2024-2034)
6 North America
6.1 North America Neuroprotective Agents Sales by Company
6.1.1 North America Neuroprotective Agents Revenue by Company (2018-2024)
6.1.2 North America Neuroprotective Agents Sales Quantity by Company (2018-2024)
6.2 North America Neuroprotective Agents Market Size by Type
6.2.1 North America Neuroprotective Agents Sales Quantity by Type (2018-2034)
6.2.2 North America Neuroprotective Agents Revenue by Type (2018-2034)
6.3 North America Neuroprotective Agents Market Size by Application
6.3.1 North America Neuroprotective Agents Sales Quantity by Application (2018-2034)
6.3.2 North America Neuroprotective Agents Revenue by Application (2018-2034)
6.4 North America Neuroprotective Agents Market Size by Country
6.4.1 North America Neuroprotective Agents Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Neuroprotective Agents Revenue by Country (2018-2034)
6.4.3 North America Neuroprotective Agents Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Neuroprotective Agents Sales by Company
7.1.1 Europe Neuroprotective Agents Sales Quantity by Company (2018-2024)
7.1.2 Europe Neuroprotective Agents Revenue by Company (2018-2024)
7.2 Europe Neuroprotective Agents Market Size by Type
7.2.1 Europe Neuroprotective Agents Sales Quantity by Type (2018-2034)
7.2.2 Europe Neuroprotective Agents Revenue by Type (2018-2034)
7.3 Europe Neuroprotective Agents Market Size by Application
7.3.1 Europe Neuroprotective Agents Sales Quantity by Application (2018-2034)
7.3.2 Europe Neuroprotective Agents Revenue by Application (2018-2034)
7.4 Europe Neuroprotective Agents Market Size by Country
7.4.1 Europe Neuroprotective Agents Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Neuroprotective Agents Revenue by Country (2018-2034)
7.4.3 Europe Neuroprotective Agents Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Neuroprotective Agents Sales by Company
8.1.1 China Neuroprotective Agents Sales Quantity by Company (2018-2024)
8.1.2 China Neuroprotective Agents Revenue by Company (2018-2024)
8.2 China Neuroprotective Agents Market Size by Type
8.2.1 China Neuroprotective Agents Sales Quantity by Type (2018-2034)
8.2.2 China Neuroprotective Agents Revenue by Type (2018-2034)
8.3 China Neuroprotective Agents Market Size by Application
8.3.1 China Neuroprotective Agents Sales Quantity by Application (2018-2034)
8.3.2 China Neuroprotective Agents Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Neuroprotective Agents Sales by Company
9.1.1 APAC Neuroprotective Agents Sales Quantity by Company (2018-2024)
9.1.2 APAC Neuroprotective Agents Revenue by Company (2018-2024)
9.2 APAC Neuroprotective Agents Market Size by Type
9.2.1 APAC Neuroprotective Agents Sales Quantity by Type (2018-2034)
9.2.2 APAC Neuroprotective Agents Revenue by Type (2018-2034)
9.3 APAC Neuroprotective Agents Market Size by Application
9.3.1 APAC Neuroprotective Agents Sales Quantity by Application (2018-2034)
9.3.2 APAC Neuroprotective Agents Revenue by Application (2018-2034)
9.4 APAC Neuroprotective Agents Market Size by Region
9.4.1 APAC Neuroprotective Agents Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Neuroprotective Agents Revenue by Region (2018-2034)
9.4.3 APAC Neuroprotective Agents Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Neuroprotective Agents Sales by Company
10.1.1 Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Neuroprotective Agents Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Neuroprotective Agents Market Size by Type
10.2.1 Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Neuroprotective Agents Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Neuroprotective Agents Market Size by Application
10.3.1 Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Neuroprotective Agents Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Neuroprotective Agents Market Size by Country
10.4.1 Middle East, Africa and Latin America Neuroprotective Agents Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Neuroprotective Agents Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Genervon Biopharmaceuticals
11.1.1 Genervon Biopharmaceuticals Company Information
11.1.2 Genervon Biopharmaceuticals Overview
11.1.3 Genervon Biopharmaceuticals Neuroprotective Agents Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Genervon Biopharmaceuticals Neuroprotective Agents Products and Services
11.1.5 Genervon Biopharmaceuticals Neuroprotective Agents SWOT Analysis
11.1.6 Genervon Biopharmaceuticals Recent Developments
11.2 NeuroVive Pharmaceutical
11.2.1 NeuroVive Pharmaceutical Company Information
11.2.2 NeuroVive Pharmaceutical Overview
11.2.3 NeuroVive Pharmaceutical Neuroprotective Agents Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 NeuroVive Pharmaceutical Neuroprotective Agents Products and Services
11.2.5 NeuroVive Pharmaceutical Neuroprotective Agents SWOT Analysis
11.2.6 NeuroVive Pharmaceutical Recent Developments
11.3 Ceregene
11.3.1 Ceregene Company Information
11.3.2 Ceregene Overview
11.3.3 Ceregene Neuroprotective Agents Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Ceregene Neuroprotective Agents Products and Services
11.3.5 Ceregene Neuroprotective Agents SWOT Analysis
11.3.6 Ceregene Recent Developments
11.4 Neuren Pharmaceuticals
11.4.1 Neuren Pharmaceuticals Company Information
11.4.2 Neuren Pharmaceuticals Overview
11.4.3 Neuren Pharmaceuticals Neuroprotective Agents Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Neuren Pharmaceuticals Neuroprotective Agents Products and Services
11.4.5 Neuren Pharmaceuticals Neuroprotective Agents SWOT Analysis
11.4.6 Neuren Pharmaceuticals Recent Developments
11.5 Allon Therapeutics
11.5.1 Allon Therapeutics Company Information
11.5.2 Allon Therapeutics Overview
11.5.3 Allon Therapeutics Neuroprotective Agents Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Allon Therapeutics Neuroprotective Agents Products and Services
11.5.5 Allon Therapeutics Neuroprotective Agents SWOT Analysis
11.5.6 Allon Therapeutics Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Neuroprotective Agents Value Chain Analysis
12.2 Neuroprotective Agents Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Neuroprotective Agents Production Mode & Process
12.4 Neuroprotective Agents Sales and Marketing
12.4.1 Neuroprotective Agents Sales Channels
12.4.2 Neuroprotective Agents Distributors
12.5 Neuroprotective Agents Customers
13 Market Dynamics
13.1 Neuroprotective Agents Industry Trends
13.2 Neuroprotective Agents Market Drivers
13.3 Neuroprotective Agents Market Challenges
13.4 Neuroprotective Agents Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Neuroprotective Agents Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Cerebrovascular Diseases
Table 3. Major Manufacturers of Neurodegenerative Disorders
Table 4. Major Manufacturers of Ophthalmic Diseases
Table 5. Major Manufacturers of Traumatic CNS Injuries
Table 6. Global Neuroprotective Agents Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Neuroprotective Agents Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Neuroprotective Agents Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Neuroprotective Agents Revenue Market Share by Region (2018-2024)
Table 10. Global Neuroprotective Agents Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Neuroprotective Agents Revenue Market Share by Region (2024-2034)
Table 12. Global Neuroprotective Agents Sales Quantity by Region: 2018 VS 2022 VS 2034 (K MT)
Table 13. Global Neuroprotective Agents Sales by Region (2018-2024) & (K MT)
Table 14. Global Neuroprotective Agents Sales Market Share by Region (2018-2024)
Table 15. Global Neuroprotective Agents Sales by Region (2024-2034) & (K MT)
Table 16. Global Neuroprotective Agents Sales Market Share by Region (2024-2034)
Table 17. Global Neuroprotective Agents Sales Quantity by Manufacturers (2018-2024) & (K MT)
Table 18. Global Neuroprotective Agents Sales Quantity Share by Manufacturers (2018-2024)
Table 19. Global Neuroprotective Agents Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Neuroprotective Agents Revenue Share by Manufacturers (2018-2024)
Table 21. Global Neuroprotective Agents Price by Manufacturers 2018-2024 (USD/MT)
Table 22. Global Key Players of Neuroprotective Agents, Industry Ranking, 2021 VS 2022
Table 23. Global Neuroprotective Agents Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Neuroprotective Agents by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroprotective Agents as of 2022)
Table 25. Global Key Manufacturers of Neuroprotective Agents, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Neuroprotective Agents, Product Offered and Application
Table 27. Global Key Manufacturers of Neuroprotective Agents, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Neuroprotective Agents Sales Quantity by Type (2018-2024) & (K MT)
Table 30. Global Neuroprotective Agents Sales Quantity by Type (2024-2034) & (K MT)
Table 31. Global Neuroprotective Agents Sales Quantity Share by Type (2018-2024)
Table 32. Global Neuroprotective Agents Sales Quantity Share by Type (2024-2034)
Table 33. Global Neuroprotective Agents Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Neuroprotective Agents Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Neuroprotective Agents Revenue Share by Type (2018-2024)
Table 36. Global Neuroprotective Agents Revenue Share by Type (2024-2034)
Table 37. Neuroprotective Agents Price by Type (2018-2024) & (USD/MT)
Table 38. Global Neuroprotective Agents Price Forecast by Type (2024-2034) & (USD/MT)
Table 39. Global Neuroprotective Agents Sales Quantity by Application (2018-2024) & (K MT)
Table 40. Global Neuroprotective Agents Sales Quantity by Application (2024-2034) & (K MT)
Table 41. Global Neuroprotective Agents Sales Quantity Share by Application (2018-2024)
Table 42. Global Neuroprotective Agents Sales Quantity Share by Application (2024-2034)
Table 43. Global Neuroprotective Agents Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Neuroprotective Agents Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Neuroprotective Agents Revenue Share by Application (2018-2024)
Table 46. Global Neuroprotective Agents Revenue Share by Application (2024-2034)
Table 47. Neuroprotective Agents Price by Application (2018-2024) & (USD/MT)
Table 48. Global Neuroprotective Agents Price Forecast by Application (2024-2034) & (USD/MT)
Table 49. North America Neuroprotective Agents Revenue by Company (2018-2024) & (US$ Million)
Table 50. North America Neuroprotective Agents Sales Quantity by Company (2018-2024) & (K MT)
Table 51. North America Neuroprotective Agents Sales Quantity by Type (2018-2024) & (K MT)
Table 52. North America Neuroprotective Agents Sales Quantity by Type (2024-2034) & (K MT)
Table 53. North America Neuroprotective Agents Revenue by Type (2018-2024) & (US$ Million)
Table 54. North America Neuroprotective Agents Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Neuroprotective Agents Sales Quantity by Application (2018-2024) & (K MT)
Table 56. North America Neuroprotective Agents Sales Quantity by Application (2024-2034) & (K MT)
Table 57. North America Neuroprotective Agents Revenue by Application (2018-2024) & (US$ Million)
Table 58. North America Neuroprotective Agents Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Neuroprotective Agents Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 60. North America Neuroprotective Agents Revenue by Country (2018-2024) & (US$ Million)
Table 61. North America Neuroprotective Agents Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Neuroprotective Agents Sales Quantity by Country (2018-2024) & (K MT)
Table 63. North America Neuroprotective Agents Sales Quantity by Country (2024-2034) & (K MT)
Table 64. Europe Neuroprotective Agents Sales Quantity by Company (2018-2024) & (K MT)
Table 65. Europe Neuroprotective Agents Revenue by Company (2018-2024) & (US$ Million)
Table 66. Europe Neuroprotective Agents Sales Quantity by Type (2018-2024) & (K MT)
Table 67. Europe Neuroprotective Agents Sales Quantity by Type (2024-2034) & (K MT)
Table 68. Europe Neuroprotective Agents Revenue by Type (2018-2024) & (US$ Million)
Table 69. Europe Neuroprotective Agents Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Neuroprotective Agents Sales Quantity by Application (2018-2024) & (K MT)
Table 71. Europe Neuroprotective Agents Sales Quantity by Application (2024-2034) & (K MT)
Table 72. Europe Neuroprotective Agents Revenue by Application (2018-2024) & (US$ Million)
Table 73. Europe Neuroprotective Agents Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Neuroprotective Agents Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 75. Europe Neuroprotective Agents Revenue by Country (2018-2024) & (US$ Million)
Table 76. Europe Neuroprotective Agents Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Neuroprotective Agents Sales Quantity by Country (2018-2024) & (K MT)
Table 78. Europe Neuroprotective Agents Sales Quantity by Country (2024-2034) & (K MT)
Table 79. China Neuroprotective Agents Sales Quantity by Company (2018-2024) & (K MT)
Table 80. China Neuroprotective Agents Revenue by Company (2018-2024) & (US$ Million)
Table 81. China Neuroprotective Agents Sales Quantity by Type (2018-2024) & (K MT)
Table 82. China Neuroprotective Agents Sales Quantity by Type (2024-2034) & (K MT)
Table 83. China Neuroprotective Agents Revenue by Type (2018-2024) & (US$ Million)
Table 84. China Neuroprotective Agents Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Neuroprotective Agents Sales Quantity by Application (2018-2024) & (K MT)
Table 86. China Neuroprotective Agents Sales Quantity by Application (2024-2034) & (K MT)
Table 87. China Neuroprotective Agents Revenue by Application (2018-2024) & (US$ Million)
Table 88. China Neuroprotective Agents Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Neuroprotective Agents Sales Quantity by Company (2018-2024) & (K MT)
Table 90. APAC Neuroprotective Agents Revenue by Company (2018-2024) & (US$ Million)
Table 91. APAC Neuroprotective Agents Sales Quantity by Type (2018-2024) & (K MT)
Table 92. APAC Neuroprotective Agents Sales Quantity by Type (2024-2034) & (K MT)
Table 93. APAC Neuroprotective Agents Revenue by Type (2018-2024) & (US$ Million)
Table 94. APAC Neuroprotective Agents Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Neuroprotective Agents Sales Quantity by Application (2018-2024) & (K MT)
Table 96. APAC Neuroprotective Agents Sales Quantity by Application (2024-2034) & (K MT)
Table 97. APAC Neuroprotective Agents Revenue by Application (2018-2024) & (US$ Million)
Table 98. APAC Neuroprotective Agents Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Neuroprotective Agents Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 100. APAC Neuroprotective Agents Revenue by Region (2018-2024) & (US$ Million)
Table 101. APAC Neuroprotective Agents Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Neuroprotective Agents Sales Quantity by Region (2018-2024) & (K MT)
Table 103. APAC Neuroprotective Agents Sales Quantity by Region (2024-2034) & (K MT)
Table 104. Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity by Company (2018-2024) & (K MT)
Table 105. Middle East, Africa and Latin America Neuroprotective Agents Revenue by Company (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity by Type (2018-2024) & (K MT)
Table 107. Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity by Type (2024-2034) & (K MT)
Table 108. Middle East, Africa and Latin America Neuroprotective Agents Revenue by Type (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America Neuroprotective Agents Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity by Application (2018-2024) & (K MT)
Table 111. Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity by Application (2024-2034) & (K MT)
Table 112. Middle East, Africa and Latin America Neuroprotective Agents Revenue by Application (2018-2024) & (US$ Million)
Table 113. Middle East, Africa and Latin America Neuroprotective Agents Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Neuroprotective Agents Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Neuroprotective Agents Revenue by Country (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America Neuroprotective Agents Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity by Country (2018-2024) & (K MT)
Table 118. Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity by Country (2024-2034) & (K MT)
Table 119. Genervon Biopharmaceuticals Company Information
Table 120. Genervon Biopharmaceuticals Description and Overview
Table 121. Genervon Biopharmaceuticals Neuroprotective Agents Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 122. Genervon Biopharmaceuticals Neuroprotective Agents Product and Services
Table 123. Genervon Biopharmaceuticals Neuroprotective Agents SWOT Analysis
Table 124. Genervon Biopharmaceuticals Recent Developments
Table 125. NeuroVive Pharmaceutical Company Information
Table 126. NeuroVive Pharmaceutical Description and Overview
Table 127. NeuroVive Pharmaceutical Neuroprotective Agents Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 128. NeuroVive Pharmaceutical Neuroprotective Agents Product and Services
Table 129. NeuroVive Pharmaceutical Neuroprotective Agents SWOT Analysis
Table 130. NeuroVive Pharmaceutical Recent Developments
Table 131. Ceregene Company Information
Table 132. Ceregene Description and Overview
Table 133. Ceregene Neuroprotective Agents Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 134. Ceregene Neuroprotective Agents Product and Services
Table 135. Ceregene Neuroprotective Agents SWOT Analysis
Table 136. Ceregene Recent Developments
Table 137. Neuren Pharmaceuticals Company Information
Table 138. Neuren Pharmaceuticals Description and Overview
Table 139. Neuren Pharmaceuticals Neuroprotective Agents Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 140. Neuren Pharmaceuticals Neuroprotective Agents Product and Services
Table 141. Neuren Pharmaceuticals Neuroprotective Agents SWOT Analysis
Table 142. Neuren Pharmaceuticals Recent Developments
Table 143. Allon Therapeutics Company Information
Table 144. Allon Therapeutics Description and Overview
Table 145. Allon Therapeutics Neuroprotective Agents Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 146. Allon Therapeutics Neuroprotective Agents Product and Services
Table 147. Allon Therapeutics Neuroprotective Agents SWOT Analysis
Table 148. Allon Therapeutics Recent Developments
Table 149. Key Raw Materials Lists
Table 150. Raw Materials Key Suppliers Lists
Table 151. Neuroprotective Agents Distributors List
Table 152. Neuroprotective Agents Customers List
Table 153. Neuroprotective Agents Market Trends
Table 154. Neuroprotective Agents Market Drivers
Table 155. Neuroprotective Agents Market Challenges
Table 156. Neuroprotective Agents Market Restraints
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Neuroprotective Agents Product Picture
Figure 2. Global Neuroprotective Agents Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Neuroprotective Agents Market Share by Type in 2022 & 2034
Figure 4. Cerebrovascular Diseases Product Picture
Figure 5. Neurodegenerative Disorders Product Picture
Figure 6. Ophthalmic Diseases Product Picture
Figure 7. Traumatic CNS Injuries Product Picture
Figure 8. Global Neuroprotective Agents Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 9. Global Neuroprotective Agents Market Share by Application in 2022 & 2034
Figure 10. Hospitals
Figure 11. Clinics
Figure 12. Others
Figure 13. Neuroprotective Agents Report Years Considered
Figure 14. Global Neuroprotective Agents Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Neuroprotective Agents Revenue 2018-2034 (US$ Million)
Figure 16. Global Neuroprotective Agents Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global Neuroprotective Agents Sales Quantity 2018-2034 (K MT)
Figure 18. Global Neuroprotective Agents Sales Quantity Market Share by Region (2018-2024)
Figure 19. Global Neuroprotective Agents Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Neuroprotective Agents Sales Quantity YoY (2018-2034) & (K MT)
Figure 21. North America Neuroprotective Agents Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Neuroprotective Agents Sales Quantity YoY (2018-2034) & (K MT)
Figure 23. Europe Neuroprotective Agents Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Neuroprotective Agents Sales Quantity YoY (2018-2034) & (K MT)
Figure 25. China Neuroprotective Agents Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Neuroprotective Agents Sales Quantity YoY (2018-2034) & (K MT)
Figure 27. APAC Neuroprotective Agents Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity YoY (2018-2034) & (K MT)
Figure 29. Middle East, Africa and Latin America Neuroprotective Agents Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Neuroprotective Agents Sales Quantity in 2022
Figure 31. The Top 10 and Top 5 Players Market Share by Neuroprotective Agents Revenue in 2022
Figure 32. Neuroprotective Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Neuroprotective Agents Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Neuroprotective Agents Revenue Market Share by Type (2018-2034)
Figure 35. Global Neuroprotective Agents Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Neuroprotective Agents Revenue Market Share by Application (2018-2034)
Figure 37. North America Neuroprotective Agents Revenue Market Share by Company in 2022
Figure 38. North America Neuroprotective Agents Sales Quantity Market Share by Company in 2022
Figure 39. North America Neuroprotective Agents Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Neuroprotective Agents Revenue Market Share by Type (2018-2034)
Figure 41. North America Neuroprotective Agents Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Neuroprotective Agents Revenue Market Share by Application (2018-2034)
Figure 43. North America Neuroprotective Agents Revenue Share by Country (2018-2034)
Figure 44. North America Neuroprotective Agents Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Neuroprotective Agents Sales Quantity Market Share by Company in 2022
Figure 48. Europe Neuroprotective Agents Revenue Market Share by Company in 2022
Figure 49. Europe Neuroprotective Agents Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Neuroprotective Agents Revenue Market Share by Type (2018-2034)
Figure 51. Europe Neuroprotective Agents Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Neuroprotective Agents Revenue Market Share by Application (2018-2034)
Figure 53. Europe Neuroprotective Agents Revenue Share by Country (2018-2034)
Figure 54. Europe Neuroprotective Agents Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 56. France Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 60. China Neuroprotective Agents Sales Quantity Market Share by Company in 2022
Figure 61. China Neuroprotective Agents Revenue Market Share by Company in 2022
Figure 62. China Neuroprotective Agents Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Neuroprotective Agents Revenue Market Share by Type (2018-2034)
Figure 64. China Neuroprotective Agents Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Neuroprotective Agents Revenue Market Share by Application (2018-2034)
Figure 66. APAC Neuroprotective Agents Sales Quantity Market Share by Company in 2022
Figure 67. APAC Neuroprotective Agents Revenue Market Share by Company in 2022
Figure 68. APAC Neuroprotective Agents Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Neuroprotective Agents Revenue Market Share by Type (2018-2034)
Figure 70. APAC Neuroprotective Agents Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Neuroprotective Agents Revenue Market Share by Application (2018-2034)
Figure 72. APAC Neuroprotective Agents Revenue Share by Region (2018-2034)
Figure 73. APAC Neuroprotective Agents Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 78. India Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Neuroprotective Agents Revenue Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Neuroprotective Agents Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Neuroprotective Agents Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Neuroprotective Agents Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Neuroprotective Agents Revenue Share by Country (2018-2034)
Figure 87. Brazil Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 92. Neuroprotective Agents Value Chain
Figure 93. Neuroprotective Agents Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed